Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
Top Cited Papers
Open Access
- 26 September 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 30 (8), 916-922
- https://doi.org/10.1093/eurheartj/ehp041
Abstract
Several studies have demonstrated that the mutant *2 allele of the CYP2C19 681G>A loss-of-function polymorphism is associated with diminished metabolization of clopidogrel into its active thiol metabolite and an attenuated platelet response to clopidogrel treatment. It is not known whether patients carrying the mutant CYP2C19*2 allele have a higher risk of stent thrombosis (ST) compared with homozygous CYP2C19*1 wild-type allele carriers following percutaneous coronary intervention (PCI). The aim of this study was to assess the impact of the CYP2C19 681G>A loss-of-function polymorphism on ST following PCI performed after pre-treatment with clopidogrel. The study population included 2485 consecutive patients undergoing coronary stent placement after pre-treatment with 600 mg of clopidogrel. Genotypes were determined with a TaqMan assay. The primary endpoint of the study was the incidence of definite ST within 30 days following PCI. Of the patients studied, 1805 (73%) were CYP2C19 wild-type homozygotes (*1/*1) and 680 (27%) carried at least one *2 allele (*1/*2 or *2/*2). The cumulative 30-day incidence of ST was significantly higher in CYP2C19*2 allele carriers (*1/*2 or *2/*2) vs. CYP2C19 wild-type homozygotes (*1/*1) [10 patients (1.5%) in CYP2C19*2 allele carriers vs. 7 (0.4%) in CYP2C19 wild-type homozygotes (*1/*1), HR 3.81, 95% CI 1.45–10.02, P = 0.007; P = 0.006 after adjustment for confounding variables]. The risk of ST was highest (2.1%) in patients with the CYP2C19 *2/*2 genotype (P = 0.002). CYP2C19*2 carrier status is significantly associated with an increased risk of ST following coronary stent placement.Keywords
This publication has 32 references indexed in Scilit:
- Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantationEuropean Heart Journal, 2008
- Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent ThrombosisJournal of the American College of Cardiology, 2007
- Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular eventsJournal of Thrombosis and Haemostasis, 2007
- Variability in Individual Responsiveness to ClopidogrelJournal of the American College of Cardiology, 2007
- Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent PlacementJournal of the American College of Cardiology, 2006
- ACC/AHA/SCAI Practice Guidelines, February 21, 2006Circulation, 2006
- Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantationJournal of the American College of Cardiology, 2005
- Variability in platelet responsiveness to clopidogrel among 544 individualsJournal of the American College of Cardiology, 2005
- Identification of the platelet ADP receptor targeted by antithrombotic drugsNature, 2001
- Identification and Biological Activity of the Active Metabolite of ClopidogrelThrombosis and Haemostasis, 2000